Page 2 - Athersys Board News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Athersys has been focused on developing a viable treatment for stroke for nearly 20 years. Read more to find out if now a good time to buy ATHX stock.

Athersys Reports First Quarter 2021 Results Search jobs Management to host conference call at 4:30 pm EDT today CLEVELAND--(BUSINESS WIRE)--$ATHX#Athersys--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2021 and provided a corporate update. “Since our recent call, we remain on track with respect to our operating plans,” stated Mr. William (B.J.) Lehmann, Jr., Interim Chief Executive Officer of Athersys. “We look forward to important progress during the remaining course of the year, including expected top-line results from the TR...

Press release content from Business Wire. The AP news staff was not involved in its creation. Athersys Announces CEO Transition CLEVELAND, Ohio--(BUSINESS WIRE)--Feb 16, 2021-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Boa...

Press release content from Business Wire. The AP news staff was not involved in its creation. Athersys Announces Cooperation Agreement With HEALIOS K.K. February 16, 2021 GMT CLEVELAND--(BUSINESS WIRE)--Feb 16, 2021-- Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of...